@article{0cc48961d9b248d79fbc21e554380ee1,
title = "Cardiovascular events and intensity of treatment in polycythemia vera",
abstract = "Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial.",
keywords = "Aged, Antineoplastic Agents, Cardiovascular Diseases, Combined Modality Therapy, Female, Follow-Up Studies, Hematocrit, Humans, Hydroxyurea, Janus Kinase 2, Male, Middle Aged, Phlebotomy, Polycythemia Vera, Thrombosis, Aged, Antineoplastic Agents, Cardiovascular Diseases, Combined Modality Therapy, Female, Follow-Up Studies, Hematocrit, Humans, Hydroxyurea, Janus Kinase 2, Male, Middle Aged, Phlebotomy, Polycythemia Vera, Thrombosis",
author = "{De Stefano}, Valerio and Roberto Marchioli and Guido Finazzi and Giorgina Specchia and Rossella Cacciola and Riccardo Cavazzina and Daniela Cilloni and Elena Elli and Alessandra Iurlo and Roberto Latagliata and Francesca Lunghi and Monia Lunghi and Marfisi, {Rosa Maria} and Pellegrino Musto and Arianna Masciulli and Caterina Musolino and Nicola Cascavilla and Giovanni Quarta and Randi, {Maria Luigia} and Davide Rapezzi and Marco Ruggeri and Elisa Rumi and Scortechini, {Anna Rita} and Simone Santini and Marco Scarano and Sergio Siragusa and Antonio Spadea and Alessia Tieghi and Emanuele Angelucci and Giuseppe Visani and Vannucchi, {Alessandro Maria} and Tiziano Barbui",
year = "2013",
doi = "10.1056/NEJMoa1208500",
language = "English",
volume = "368",
pages = "22--33",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachusetts Medical Society:860 Winter Street:Waltham, MA 02451:(800)843-6356, (781)893-3800, EMAIL: nejmcust@mms.org, INTERNET: http://www.massmed.org/, Fax: (781)647-5785, (781)893-7368",
}